Amedisys (AMED)
(Delayed Data from NSDQ)
$96.87 USD
-0.43 (-0.44%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $96.88 +0.01 (0.01%) 7:26 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Company Summary
Amedisys Inc. provides home health and hospice services throughout the U.S. to the growing chronic, co-morbid, and aging American population. The company also offers clinically focused programs for chronic conditions and various diseases such as diabetes, coronary artery disease, as well as various rehabilitative programs. It provides hospice services to patients through an interdisciplinary care team which includes nurse practitioners and other skilled nurses, social workers, aides, bereavement counselors and chaplains. Amedisys was founded in 1982 and is headquartered in Baton Rouge, LA.
The company depends on reimbursement from Medicare (for chronic care) for ...
Company Summary
Amedisys Inc. provides home health and hospice services throughout the U.S. to the growing chronic, co-morbid, and aging American population. The company also offers clinically focused programs for chronic conditions and various diseases such as diabetes, coronary artery disease, as well as various rehabilitative programs. It provides hospice services to patients through an interdisciplinary care team which includes nurse practitioners and other skilled nurses, social workers, aides, bereavement counselors and chaplains. Amedisys was founded in 1982 and is headquartered in Baton Rouge, LA.
The company depends on reimbursement from Medicare (for chronic care) for a significant portion of its revenues on account of the age demographics of its patient base (average age of 81). Medicare represented approximately 73% to 75% of Amedisys’ net service revenues in the last three years.
Amedisys plans to diversify its payment sources and become less reliant upon Medicare, based on the needs of the aging population, uncertainty surrounding health care reform, and new health care models currently in development, such as Accountable Care Organizations (ACOs).
The company operates through three business segments:
Home Health segment: This comprised 62.8% of total revenues in 2023, up 2.4% from 2022. The business delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery.
Hospice segment (35.7% of 2023 revenues, up 1.4%): This provides care that is designed to provide comfort and support for those who are facing a terminal illness.
High Acuity Care segment (0.8% of 2023 revenues, up 54.5%): This was formed post the acquisition of Contessa Health ("Contessa") during August 2021. The segment delivers the essential elements of inpatient hospital, skilled nursing facility (SNF) care and palliative care to patients in their homes.
Amedisys previously operated a Personal Care segment, which provided patients with assistance with the essential activities of daily living. However, in February 2023, the company signed a definitive agreement to sell the business (excluding the Florida operations) to HouseWorks, LLC. The divestment was subsequently completed on Mar 31, 2023.
General Information
Amedisys, Inc
3854 AMERICAN WAY SUITE A
BATON ROUGE, LA 70816
Phone: 225-292-2031
Fax: 225-292-8163
Email: ir@amedisys.com
Industry | Medical - Outpatient and Home Healthcare |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 10/22/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.14 |
Current Year EPS Consensus Estimate | 4.66 |
Estimated Long-Term EPS Growth Rate | 11.00 |
Exp Earnings Date | 10/22/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 97.30 |
52 Week High | 98.95 |
52 Week Low | 89.55 |
Beta | 0.78 |
20 Day Moving Average | 325,144.94 |
Target Price Consensus | 100.88 |
4 Week | -0.27 |
12 Week | 5.99 |
YTD | 2.36 |
4 Week | -1.45 |
12 Week | 1.49 |
YTD | -14.39 |
Shares Outstanding (millions) | 32.74 |
Market Capitalization (millions) | 3,185.66 |
Short Ratio | NA |
Last Split Date | 12/5/2006 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 20.88 |
Trailing 12 Months | 22.79 |
PEG Ratio | 1.90 |
vs. Previous Year | -3.65% |
vs. Previous Quarter | 28.16% |
vs. Previous Year | 6.91% |
vs. Previous Quarter | 3.46% |
Price/Book | 2.70 |
Price/Cash Flow | 15.92 |
Price / Sales | 1.39 |
6/30/24 | 12.39 |
3/31/24 | 12.85 |
12/31/23 | 12.76 |
6/30/24 | 6.78 |
3/31/24 | 6.95 |
12/31/23 | 7.02 |
6/30/24 | 1.16 |
3/31/24 | 1.09 |
12/31/23 | 1.05 |
6/30/24 | 1.16 |
3/31/24 | 1.09 |
12/31/23 | 1.05 |
6/30/24 | 6.14 |
3/31/24 | 6.30 |
12/31/23 | 6.29 |
6/30/24 | 4.02 |
3/31/24 | -0.91 |
12/31/23 | -0.44 |
6/30/24 | 6.27 |
3/31/24 | 1.43 |
12/31/23 | 1.77 |
6/30/24 | 36.01 |
3/31/24 | 34.97 |
12/31/23 | 34.31 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | 0.30 |
3/31/24 | 0.31 |
12/31/23 | 0.32 |
6/30/24 | 22.97 |
3/31/24 | 23.76 |
12/31/23 | 24.42 |